A new study by University of Bath scientists has highlighted two new potential families of drug molecules that could open the ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

BASEL, Switzerland I July 02, 2025 I BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of ...